Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
801
Views
0
CrossRef citations to date
0
Altmetric
Author’s View

PD-L1+ macrophages suppress T cell-mediated anticancer immunity

Peng Liua Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, FranceView further author information
,
Liwei Zhaoa Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, FranceView further author information
,
Guido Kroemera Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France;c Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, FranceCorrespondence[email protected]
View further author information
&
Oliver Keppa Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6081-9558View further author information
ORCID Icon
Article: 2338951 | Received 04 Mar 2024, Accepted 01 Apr 2024, Published online: 04 Apr 2024

References

  • Pan H, Liu P, Kroemer G, Kepp O. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy. Int Rev Cell Mol Biol. 2024;382:279–3.
  • Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z.
  • Zhao L, Zhang S, Kepp O, Kroemer G, Liu P. Dendritic cell transfer for cancer immunotherapy. Int Rev Cell Mol Biol. 2022;370:33–64.
  • Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends In Immunology. 2017;38(8):577–593. doi:10.1016/j.it.2017.05.006.
  • Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology. 2022;11(1):2096363. doi:10.1080/2162402X.2022.2096363.
  • Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F. et al. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. J Immunother Cancer. 2021;9(5):e002432. doi:10.1136/jitc-2021-002432.
  • Sprooten J, Vanmeerbeek I, Datsi A, Govaerts J, Naulaerts S, Laureano RS, Borràs DM, Calvet A, Malviya V, Kuballa M. et al. Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells. Cell Reports Medicine. 2024;5(1):101377. doi:10.1016/j.xcrm.2023.101377.
  • Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X. et al. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022;10(6):e004400. doi:10.1136/jitc-2021-004400.
  • Hensler M, Rakova J, Kasikova L, Lanickova T, Pasulka J, Holicek P, Hraska M, Hrnciarova T, Kadlecova P, Schoenenberger A. et al. Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. Oncoimmunology. 2022;11(1):2101596. doi:10.1080/2162402X.2022.2101596.
  • Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T. et al. An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors. Clin Cancer Res. 2022;28(14):3053–3065. doi:10.1158/1078-0432.CCR-21-4413.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.